Showing results (801-810 of 1,995) with videos related to
Sort By:
Pageof 200
The Lancet. Neurology|April 13, 2013
Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional studyFaisal Mohammad Amin, Mohammad Sohail Asghar, Anders Hougaard, et al.The Lancet. Neurology|February 19, 2013
Manifestations of HIV infection in the peripheral nervous systemChad M Centner, Kathleen J Bateman, Jeannine M HeckmannThe Lancet. Neurology|February 9, 2013
The natural history of multiple system atrophy: a prospective European cohort studyGregor K Wenning, Felix Geser, Florian Krismer, et al.The Lancet. Neurology|February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Axel Rominger, Peter Bartenstein, et al.The Lancet. Neurology|December 25, 2012
A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trialPhillip A Scott, William J Meurer, Shirley M Frederiksen, et al.The Lancet. Neurology|December 15, 2012
Genetic insights in Alzheimer's diseaseKarolien Bettens, Kristel Sleegers, Christine Van BroeckhovenThe Lancet. Neurology|December 4, 2012
Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort studyJose A Pineda, Jeffrey R Leonard, Ioanna G Mazotas, et al.The Lancet. Neurology|October 10, 2014
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trialMerit E Cudkowicz, Sarah Titus, Marianne Kearney, et al.The Lancet. Neurology|October 10, 2014
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trialDavid Wilkinson, Kristian Windfeld, Eskild Colding-JørgensenThe Lancet. Neurology|October 16, 2014
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?Hiroshi Mitsumoto, Benjamin R Brooks, Vincenzo SilaniPageof 200